Objective: Strategies to reduce Retinopathy of Prematurity (ROP) have focused primarily on respiratory management. Hyperglycemia (HG) and insulin use, risk factors for adult diabetic retinopathy, as well as growth rates may be modifiable variables useful to reduce ROP. ) done in the first 29 days of life were collected for analysis.
Introduction
Retinopathy of Prematurity (ROP) is an important morbidity in premature infants because it is highly predictive of subsequent visual defects and neurodevelopmental impairment. 1, 2 Although there is evidence that tighter control of oxygen use and hemoglobin saturation can reduce ROP, 3 and pharmacologic measures might lessen the rate, 4 the incidence of stage 3 to 4 ROP continues to be a major morbidity in 10% of infants born at <30 weeks postmenstrual age (PMA). 5 In an effort to improve growth in premature infants, our neonatal intensive care unit (NICU) adopted more aggressive nutrition practices in 2003. These measures included using day 1 starter hyperalimentation and faster advancement of intravenous glucose, protein and fat. 6 With no change in the gestational age profile, we noted a concomitant increase in hyperglycemia (HG) and insulin use, and our rate of stage 3 to 4 ROP in infants born at <30 weeks PMA increased from 4% in 2001 to 2002 to 9% in 2006 to 2007 (P ¼ 0.085, unpublished observation). Three previous reports have suggested a relationship between HG and ROP, [7] [8] [9] and there are data linking slower NICU weight gain to ROP, 10 thus we hypothesized our nutrition practices may be adversely affecting our ROP rate. Notably, our NICU has practiced oxygen saturation targeting since 2001, has a breast milk usage rate of 95%, does not use erythropoietin, and uses postnatal corticosteroids sparingly, thus important risk factors for ROP were relatively minimized during the study period, allowing us to focus on HG, insulin use and growth. This retrospective analysis was conducted to answer a specific question: After adjusting for the principle risk factors for ROP (for example, gestational age and lung disease severity), do blood glucose levels and/or insulin use and/or growth rates predict the incidence and/or severity of ROP?
Methods
Approval for this retrospective chart review and analysis was obtained from our institutional review board. The Providence St Vincent Medical Center NICU has never diagnosed stage 3 or 4 ROP in any infant born at 30 weeks PMA or beyond so study subjects included all infants 29 6/7 weeks PMA or less, born on 1 January 2003 through 31 December 2007, who had at least one retinal exam and survived to discharge. First eye exams were done at 5 to 6 weeks of age or discharge, whichever came first, then every 2 weeks until retinal maturity. ROP was categorized as none, mild (stage 1 or 2) or severe (stage 3 or 4) using the International Classification.
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All infants were begun on starter hyperalimention the day of birth, with intravenous fat added on day 2. Intravenous nutrients were increased to reach daily goals of B90 to 110 total kcal per kg, 3.5 g of protein per kg and 3 g of fat per kg by 1 week of age. Enteral feeds of breast milk were begun on day 2 or 3, and advanced by 10 to 15 ml kg À1 per day as tolerated. Intravenous fluids were concomitantly weaned, to target the total fluid intake at 125 to 150 ml per kg per day, total kcal at 120 to 130 kcal kg À1 per day. 95% of our infants received breast milk as the primary feeding. To ascertain a more sensitive statistical measure of fetal growth restriction, we calculated the observed/expected 50th percentile birth weight ratio (O/E) for each infant rather than just recording yes or no as to whether an infant was above or below a given percentile. To measure weight gain, we used the exponential calculation of growth velocity developed by Patel et al. 12 and employed by all participant NICUs in the Vermont Oxford Network. Length and head circumference were measured weekly.
All infants had bedside whole-blood glucose determinations (BG) done every 3 to 6 h (Hemocue, Lake Forest, CA, USA). The majority of the samples were obtained by warmed heel stick, but arterial or venous blood was used when a central catheter infusing non-glucose intravenous fluids was present. Our target BG was 60 to 180 mg dl À1 (3.3 to 10 mmol l À1 ). If BGs were stable (hereafter in mg dl À1 ), measurements were done less often as enteral feedings were increased, but BGs were always done at least every 6 to 24 h as along as intravenous glucose was administered.
HG was arbitrarily defined as mild (BG 151 to 180), moderate (181 to 210) or severe (>210). Although we did not employ a rigid protocol, insulin was generally started if two consecutive BGs were >180 to 210, and the dose was generally 0.02 to 0.10 U kg À1 h À1 . Although additional data would have been helpful for an even more detailed analysis, this was a retrospective review of 372 infants which entailed reviewing thousands of daily flow sheets, thus we elected to not calculate the exact insulin dose and glucose infusion rate for each of the BG values. Insulin was weaned off as the BG stabilized below 150, intravenous glucose was tapered and full enteral feeds reached. The first 29 days of life were selected as the study period because our chart review revealed almost no insulin use beyond 1 month of age.
We considered several methods to best represent the BG data including area under the curve calculations, determining the percentage of BGs exceeding target levels, and the mean and s.d. fluctuations of all BGs. Working within the limitations of a retrospective investigation, our statistical analysis suggested that the best representative value was the mean BG calculated each day as the average of all BGs done in that 24 h period, as this minimized overrepresentation of high and low values. We analyzed the relationship between ROP and daily mean BG in the first 7 days only, first 14 days, first 21 days, and in the full 29 days. It turned out that the full 29 days was the most informative, so we calculated the mean of the 29 daily mean BGs and used this in the statistical analysis. We also analyzed the proportion of BGs in each ROP category that exceeded 150, 180 and 210. The total days in which insulin was given was calculated, and in an attempt to separate the effects of HG and insulin, we determined the number of days in which the mean BG was >180 but no insulin was given, and conversely the number of days in which the mean BG was <151 but insulin was given.
As respiratory disease is a major risk factor for ROP, 1,3 we included five markers of lung disease severity in our analysis: (a) chronic lung disease defined as supplemental oxygen use at 36-week PMA because room air transcutaneous saturations were <90%, (b) supplemental oxygen days, (c) nasal continuous positive airway pressure days, (d) mechanical ventilation days and (e) corticosteroids for chronic lung disease. Our NICU used pulse oximetry for hemoglobin saturation targeting on all infants during the study period, with our goal 86 to 94%. Postnatal corticosteroid use was 7% and no erythropoietin was used. w 2 -tests were used to compare categorical variables. For continuous variables one-way analysis of variance or the KruskalWallis test was used. Ordinal logistic regression with proportional odds model was used to determine the predictors for severity of ROP (ordered as none, mild ROP or severe ROP). The proportional odds model assumption implies that the odds ratio is the same regardless of the cutoff point chosen to dichotomize the independent variable. In this study, it assumes the odds ratio is the same for mild plus severe ROP versus none, and severe ROP versus mild ROP plus none. P-values <0.05 were used for variable selection in the mode. Likelihood ratio test and Akaike Information Criterion were used for model comparison. C-statistic was used to measure model discrimination. 13 A qualitative description of the discrimination of the c-statistic is: 0.5 ¼ none, 0.7 to 0.8 ¼ acceptable, 0.8 to 0.9 ¼ excellent, >0.9 ¼ outstanding and 1.0 ¼ perfect. Results are presented using odds ratios with 95% confidence intervals. Statistical analysis was performed using PASW 17 (SPSS, Chicago, IL, USA), Stata 10 (Statcorp, College Station, TX, USA) and R 2.9 (http://www.R-project.org).
Results
In all, 372 infants were born at <30 0/7 weeks PMA, mean (s.d.) age 27.6 (1.4) weeks, mean (s.d.) weight 994 (242) g, had at least one retinal exam, and were discharged alive from the NICU. 42 Other infants were excluded from analysis because of death or discharge before the first retinal exam. No infant progressed from mild ROP to severe ROP after hospital discharge. (median BGs per infant 41, range 7 to 175), and the use of insulin compared with the severity of ROP. Infants with higher stages of ROP had a greater 29-day mean BG, more episodes of all three levels of HG, and greater daily exposure to insulin. 137 (37%) infants received at least 1 day of insulin (median 9, range 1 to 26). Infants with more severe ROP had a greater number of insulin days associated with a daily mean BG <151. Conversely, there was no significant difference among the three ROP categories in terms of number of days with the daily mean BG>180 but no insulin given. Figure 1 is an attempt to graphically display the multidimensional relationship between PMA at birth, BG, insulin exposure and ROP. Infants with more severe stages of ROP were more premature, had higher 29-day mean BG and had more days on insulin.
We used ordinal logistic regression to identify the predictors for severity of ROP using the clinical variables listed in Table 1 as adjusters as well as including 29-day mean BG and insulin days. To evaluate the impact of BG, we first fit the model with BG and the other clinical variables, but insulin was purposely withheld from the model (Table 3) . PMA, male gender, birth weight O/E ratio, growth velocity, and 29-day mean BG were found to be significant predictors (Model A). However, when days on insulin were allowed to come into the model, it displaced BG (Model B). Finally, when BG was forced back into the model (Model C) it had very little effect. The likelihood ratio test showed Model C to be significantly better than Model A, but not significantly better than Model B. A global comparison of these models, the Akaike Information Criterion statistic, which penalizes for non-parsimony, shows model B to be the best of these models. The c-statistic showed that Model B and C had higher discrimination ability than Model A. On the basis of the proportional odds assumption, the odds ratios were the same for mild plus severe ROP versus none, and severe ROP versus mild ROP plus none. BG and insulin were Figure 1 The multidimensional relationship of PMA at birth, 29-day mean blood glucose, insulin exposure and retinopathy of prematurity. The areas of circles are proportional to the number of days on insulin, and infants who never received insulin are represented by an 'x'. both highly significant risk factors for ROP, but in all models insulin was stronger and forced BG out.
Discussion
Our retrospective chart review of 372 infants born at <30-week PMA demonstrates that higher mean BG, the number and severity of hyperglycemic episodes, and exogenous insulin use in the first 29 days of life are all predictive of an increased risk of mild (stage 1 to 2) and severe (stage 3 to 4) ROP (Table 2) . Furthermore, stepwise multiple regression analysis adjusted for the principle confounding ROP risk factors including PMA, gender, birth weight, growth restriction, growth rate, and severity markers of lung disease (Tables 1 and 3) , indicates elevated BG and insulin use to be significantly associated with ROP.
In a retrospective, non-controlled study like ours, it is difficult to separate an independent effect of exogenous insulin apart from HG because insulin was generally started when BG rose above 180 to 210 and then typically resulted in a lowering of the BG. Interestingly, our analysis shows that insulin use, adjusted for BG, was even more predictive of mild and severe ROP than BG alone ( Table 3 ), and that insulin use when the daily BG averaged <151 was associated with ROP (Table 2) .
Garg et al. 7 first reported a possible link between ROP and HG in a retrospective study matching 16 infants born at <1000 g who developed severe ROP with 32 case controls. They found each 10 mg dl À1 increase in BG noted in the first month of life significantly increased the risk of ROP. Ertl et al. 8 demonstrated a similar finding in a retrospective review of 201 premature infants, 71 of whom developed ROP. Regression analysis showed that HG (defined as BG >153) was an independent risk factor for ROP. 8 Blanco, in a retrospective review of 169 infants born at <1000 g, showed that HG (BG>150) in the first 15 days of life was associated with 4.6-fold increase in the risk for ROP. 9 Although the association between HG and ROP has been previously reported, we believe our analysis strengthens the link significantly for several clinically relevant reasons. First, ours is the largest study to date in terms of total number of infants included, all born at <30 weeks PMA, and with the largest number of infants who subsequently developed ROP. Second, we included every BG done in the first 29 days of life and noted whether insulin was being administered. Third, our NICU consistently ranks among the top 5% in the entire Vermont Oxford Network for risk adjusted survival without major morbidities in very low-birth weight infants.
14 Important co-morbidities associated with ROP such as chronic lung disease, nosocomial sepsis, and intraventricular hemorrhage are less prominent in our NICU compared with most, thus making our regression analysis less complicated by confounders (Table 1) . Fourth, we employed transcutaneous oxygen saturation targeting with continuous pulse oximetry in all infants aiming for values of 86 to 94%, had very high breast milk use, used comparatively little postnatal corticosteroids, and did not use erythropoietin, thus employing four strategies shown to reduce ROP risk. 3, 15, 16, 17 Fifth, our investigation is the first to incorporate BG values, insulin use, and NICU growth data into the multiple regression risk analysis for ROP.
Poorly controlled BG is a known risk factor for adult diabetic retinopathy. 18 Persistent low insulin-like growth factor I levels in premature infants have been shown to be strongly associated with the later development of ROP. 19 Hellstrom 20 and Smith 21 have demonstrated early low insulin-like growth factor I levels to be associated with a later elevation of vascular endothelial growth factor, a prime determinant of ROP. Beardsall showed that early elective insulin therapy in premature infants can both reduce HG and increase insulin-like growth factor I which theoretically should decrease ROP. 22 However, in a subsequent investigation, Beardsall et al. 23 was unable to show clinical benefit from a higher fixed-dose insulin therapy, despite lower BG levels in the treatment group. Although the severe ROP rate was not significantly lower in the insulin treatment group, the ROP rate was a predetermined secondary outcome, the study period was just the first 7 days of life, and 36% of the control group received insulin therapy because of HG.
Our investigation is the first to examine the relationship between ROP and HG, insulin use, and NICU growth data. Our results are in agreement with the finding of Allegaert that fetal growth restriction is associated with ROP, 24 and our ordinal regression analysis suggests that slower growth velocity during the NICU stay is also predictive of ROP (Table 3) . Interestingly, severity markers of lung disease which are well-described traditional univariate predictors of ROP (Table 1) do not figure into our final regression analysis when BG, insulin, and growth velocity were accounted for (Table 3 ). This is in agreement with the findings of Lofqvist 25 and Hellstrom 10 that weight gain (combined with IGF-1 measurements in the study of Lofqvist et al. 25 ) is highly sensitive in predicting proliferative ROP. We did not measure IGF-1, thus can only speculate as to the complex relationship between fetal and neonatal growth, IGF-1, HG, insulin and the development of ROP. In contrast to the finding of Lofqvist et al., 26 we did not find slower head growth to be predictive of ROP, in addition, we found no relationship with length measurements. Our finding that insulin use is a stronger predictor of ROP than HG has not been previously reported, but is consistent with the observation of Poulaki et al. 27 that insulin therapy worsens diabetic retinopathy. Whether or not attempts to improve postnatal growth rates by utilizing more aggressive intravenous nutrition, enteral feedings, and/or insulin therapy have an effect on ROP and other morbidities is speculative at this point thus we have chosen not to alter our present clinical management guidelines until more explanatory data are available.
Limitations of our investigation include the retrospective design, which can only determine correlation and not causation between BG or insulin, and ROP. We cannot be assured that every confounding variable that might affect ROP was accounted for. Our BG monitoring and insulin dosing protocols were not strictly standardized thus making detailed analyses of BG and insulin and their relationship to ROP difficult. Although we have guidelines for nutritional therapy, BG management and insulin use, much bedside decision making was left to the discretion of the clinicians.
Although certain risk factors for ROP are well established, and we have reason to believe HG, insulin, and slow growth to be in that group, Figure 1 illustrates the complexity of pathogenesis theories. Note the infant in the upper panel left, born at 24 6/7 weeks PMA, 29-day mean BG 137 and 17 days of insulin use, yet no ROP developed. Conversely, note the infant in the lower panel right born at 28 0/7 weeks PMA, 29-day mean BG 100 and 0 insulin days, yet severe ROP developed.
Conclusion
Our retrospective investigation strengthens the biologically plausible link between HG, insulin therapy, growth velocity, and the development of ROP. Management guidelines in the first weeks of life that promote proper growth, while maintaining euglycemia may be a potentially better practice to reduce ROP. A properly designed randomized, controlled trial using formal hyperalimentation and feeding guidelines, close BG monitoring, insulin therapy for strictly defined HG, and close tracking of growth, nutrition, and co-morbidities is warranted.
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